Endo International PLC (NASDAQ:ENDP) updated its FY16 earnings guidance on Friday. The company provided earnings per share guidance of $4.50-4.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.56. The company issued revenue guidance of $3.87-4.03 billion, compared to the consensus revenue estimate of $3.93 billion.Endo International PLC also updated its Q3 guidance to $0.77-0.82 EPS.

A number of research firms have recently commented on ENDP. JPMorgan Chase & Co. set a $40.00 price target on Endo International PLC and gave the stock a buy rating in a report on Tuesday, August 9th. Leerink Swann reaffirmed a hold rating and issued a $22.00 price target (down from $23.00) on shares of Endo International PLC in a report on Tuesday, August 9th. Oppenheimer Holdings Inc. reaffirmed a hold rating on shares of Endo International PLC in a report on Wednesday, June 29th. Mizuho raised Endo International PLC from a neutral rating to a buy rating and raised their price target for the stock from $16.00 to $29.00 in a report on Friday, August 12th. Finally, Vetr lowered Endo International PLC from a strong-buy rating to a buy rating and set a $19.14 price target for the company. in a report on Thursday, July 7th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the stock. Endo International PLC currently has a consensus rating of Hold and an average target price of $39.32.

Shares of Endo International PLC (NASDAQ:ENDP) opened at 20.26 on Friday. The firm’s 50-day moving average price is $21.12 and its 200 day moving average price is $22.00. Endo International PLC has a 52-week low of $12.56 and a 52-week high of $74.70. The company’s market capitalization is $4.51 billion.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Monday, August 8th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.74 by $0.12. Endo International PLC had a negative net margin of 25.90% and a positive return on equity of 15.54%. The business earned $921 million during the quarter, compared to the consensus estimate of $873.50 million. During the same quarter in the prior year, the firm earned $1.08 EPS. The business’s revenue was up 25.3% on a year-over-year basis. On average, equities analysts forecast that Endo International PLC will post $4.56 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its position in Endo International PLC by 9.3% in the second quarter. State Street Corp now owns 9,430,866 shares of the company’s stock valued at $147,021,000 after buying an additional 805,101 shares during the period. Marshall Wace LLP increased its position in Endo International PLC by 814.0% in the second quarter. Marshall Wace LLP now owns 73,821 shares of the company’s stock valued at $1,151,000 after buying an additional 65,744 shares during the period. Van ECK Associates Corp increased its position in Endo International PLC by 54.1% in the second quarter. Van ECK Associates Corp now owns 117,695 shares of the company’s stock valued at $1,835,000 after buying an additional 41,331 shares during the period. Tredje AP fonden increased its position in Endo International PLC by 123.3% in the second quarter. Tredje AP fonden now owns 57,835 shares of the company’s stock valued at $902,000 after buying an additional 31,935 shares during the period. Finally, Sentry Investment Management LLC increased its position in Endo International PLC by 191.5% in the second quarter. Sentry Investment Management LLC now owns 46,925 shares of the company’s stock valued at $732,000 after buying an additional 30,826 shares during the period. 96.64% of the stock is owned by institutional investors and hedge funds.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

5 Day Chart for NASDAQ:ENDP

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.